Ticker Details
ACADIA Pharmaceuticals Inc. ACADIA Pharmaceuticals Inc is a biotechnology company which develops and commercializes biopharmaceutical products to address central nervous system disorders. It aims to discover small molecule drugs to address Parkinson's, Alzheimer's and schizophrenia.
IPO Date:	June 1, 2004
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$4.06B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.44 | 2.65%
Avg Daily Range (30 D):	$0.52 | 2.10%
Avg Daily Range (90 D):	$0.46 | 1.92%

Institutional Daily Volume
Avg Daily Volume:	1.22M
Avg Daily Volume (30 D):	1.08M
Avg Daily Volume (90 D):	1.18M

Trade Size
Avg Trade Size (Sh.):	128
Avg Trade Size (Sh.) (30 D):	57
Avg Trade Size (Sh.) (90 D):	61

Institutional Trades
Total Institutional Trades:	10,188
Avg Institutional Trade:	$2.32M
Avg Institutional Trade (30 D):	$3.6M
Avg Institutional Trade (90 D):	$3.53M
Avg Institutional Trade Volume:	.1M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$4.24M
Avg Closing Trade (30 D):	$6.35M
Avg Closing Trade (90 D):	$6.89M
Avg Closing Volume:	175.97K

News

Dec 4, 2025 @ 12:12 AM Acadia Stock Up 59% in a Year — Is a $51 Mi... Source: Jonathan Ponciano

Sep 11, 2025 @ 3:30 AM Questex’s Fierce Pharma Announces the 2025 ... Source: Linda Lam

Apr 22, 2025 @ 5:00 PM Parkinson’s Disease Therapeutic Domain Proj... Source: Delveinsight

Feb 11, 2025 @ 8:48 AM Neuroregeneration Therapy Market to Surpass USD 64... Source: Transparency Market Research

Jun 27, 2024 @ 12:41 PM This Vertex Pharmaceuticals Analyst Begins Coverag... Source: Avi Kapoor

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS		$.43	$.16
Diluted EPS		$.42	$.16
Revenue		$278.63M	$264.57M
Gross Profit		$256.99M	$243.83M
Net Income / Loss		$71.78M	$26.67M
Operating Income / Loss		$35.76M	$32.37M
Cost of Revenue		$21.65M	$20.73M
Net Cash Flow		$4.36M	$36.62M
PE Ratio